Rebecca Le Flufy, Ross McNaughton and Adrian Toutoungi from Taylor Wessing LLP review the potential impacts of the UK’s National Security and Investment Bill on the life sciences industry and how it could influence future deals.
The National Security and Investment Bill was laid before Parliament by the UK Government on 11 November 2020. The Bill will establish a dual regime for transactions that could give rise to national security concerns. The dual regime will consist of both a mandatory notification regime for transactions in 17 sensitive sectors (at least three of which could catch transactions in the life sciences sector) and a voluntary regime coupled with a call-in power for the Government, allowing it to examine transactions which may give rise to national security concerns. Importantly, this call-in power will have retrospective application, meaning that once the Bill becomes law, the Government will be able to call-in transactions which completed from 12 November 2020 onwards if it considers that they could raise national security concerns.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
The Bill went through the readings in the House of Commons with no amendments. It is currently being debated in the House of Lords but there have been no significant amendments. If the Bill comes into force as currently drafted, we expect it will have a significant impact on businesses operating in the life sciences sectors; particularly in the context of M&A (mergers and acquisitions) transactions and funding rounds as well as intellectual property licensing. We are expecting it to become law in the second half of 2021.
Mandatory notification regime
Sensitive sectors
The mandatory notification regime will not come into force until the Bill becomes law. The regime provides that an acquiror or investor must make a mandatory notification to BEIS (The Department for Business, Energy & Industrial Strategy) if there is a transaction involving a ‘notifiable acquisition’ in 17 specified sensitive sectors.
“If the Bill comes into force as currently drafted, we expect it will have a significant impact on businesses operating in the life sciences sectors”
‘Engineering Biology’ was included as one of these sensitive sectors in the first iteration of the definitions, but was considered to be so widely drawn that it arguably covered all of the biotech sector. Following a public consultation on the definitions of the 17 sensitive sectors, this definition has been narrowed to ‘Synthetic Biology’ and certain areas which do not pose a national security risk have been specifically excluded, including diagnostics, industrial biotechnology, food-related production, general services and certain aspects of gene therapy and cell therapy. This brings a welcome improvement in clarity. Interestingly, the express reference to vaccines has also been dropped.
In the Government’s consultation response, they have made it clear that they think the narrowed approach strikes the appropriate balance between ensuring the UK has appropriate safeguards in place to protect national security while also promoting the UK’s bioengineering sector in the UK and abroad. In particular, the consultation noted that the rapidity of the sector’s development and the dual-use nature of synthetic biology make it difficult for the Government to monitor which transactions may pose a risk to national security to the degree necessary to be able to ‘call-in’ transactions and, as such, it requires that transactions are mandatorily notified.
However, transactions in the life sciences sector may also be caught if they fall in another specified sensitive sector and, for example, the definitions of artificial intelligence and critical suppliers to government or the emergency services, in particular, are potentially most likely to be relevant here. Again, the definitions of these sectors were narrowed following the consultation but still remain relatively broad.
Notifiable acquisitions
Notifiable acquisitions will be those where, in relation to an entity:
1. there is an increase of shareholding or voting rights from:
less than 15 percent to 15 percent or more
25 percent or less to more than 25 percent
50 percent or less to more than 50 percent
less than 75 percent to 75 percent or more, or
2. the acquisition of voting rights that enable or prevent the passage of any class of resolution governing the affairs of the entity being acquired.
Notification will be required irrespective of whether the transaction raises national security issues or not. Given the low thresholds for notification and the broad definitions of the sensitive sectors, we expect that a relatively large number of transactions in the life sciences sector could be caught by the mandatory notification regime. For example, initial investment rounds for early-stage companies commonly include at least one party taking a 15 percent or more equity stake and we would therefore expect notification to be required in almost every early-stage investment round to the extent covered by the definitions, including in synthetic biology.
If a transaction is caught under the regime, it must not complete until clearance has been obtained from the Secretary of State. If a notifiable transaction is not notified or completes prior to obtaining clearance, it will be void and significant sanctions may apply. The process for obtaining clearance is explained further below.
Voluntary notification regime
Voluntary notifications
For other sectors of the economy that are not among those 17 sensitive sectors, an acquiror or investor can make a voluntary notification if there is a ‘trigger event’ and a risk to national security.
Trigger events
A trigger event under the voluntary notification regime has some differences to a notifiable acquisition under the mandatory regime. In relation to entities, the same 25 percent, 50 percent and 75 percent thresholds apply. There is no 15 percent threshold as in the mandatory regime but there is a ‘material influence’ trigger, applicable where a person acquires the power to materially influence the policy of the target. Given the nature of the rights that venture capital investors in growth businesses seek, it is quite possible that they could be caught by this material influence test at shareholding levels below 25 percent.
Unlike notifiable acquisitions, trigger events can also apply in relation to an asset. A trigger event will occur in relation to an asset where a person acquires a right or interest in, or in relation to, the asset and as a result they are able to use the asset, or direct or control how the asset is used (or if they increase their ability to use or control it). This could capture all manner of intellectual property licensing, including licensing-in intellectual property from universities or research institutes and licensing on a non-exclusive basis. Although there is no mandatory notification, parties will need to consider if there is any chance that such licensing could be considered to give rise to national security concerns and should notify if so.
It is possible, under the draft Bill, that intellectual property licensing could come under the purview of the mandatory notification regime in the future, although advisors and industry bodies are advocating against this.
For any transaction that is not notified, the Government will be able to retroactively call-in any transactions closing from 12 November 2020 for up to five years after completion if there is a trigger event and there are potential national security concerns, provided it acts within six months of becoming aware of the transaction (for example, from the press).
Process for review
Once the Government has accepted a notification under either the voluntary or mandatory notification procedure, it has six weeks to either issue a clearance notice or call in the transaction for further review. Before accepting the notification, however, it can request further information, such that the actual time period could be longer than six weeks. Even if the six-week deadline is met, we expect that this will cause significant delays to transactions such as funding rounds and companies will need to build the notification procedure into their transaction timetables. The open-ended timeframe for an acceptance of a notification also poses cause for concern.
If the Government does issue a call-in notice (either following a notification or using its call-in power for transactions that have not been notified) it has a period of 30 working days (which can be extended by up to a further 45 working days or more in certain circumstances) within which to review the transaction and decide whether or not to clear it.
Following the review, the Government may either issue a clearance notice, clear the transaction subject to conditions, prohibit it or, if the transaction has completed, order it to be unwound.
Final thoughts
The consequences of a transaction becoming void (under the mandatory notification regime) or of it being unwound up to five years after completion (under the call-in power) are severe and potentially costly. Investors and acquirors are therefore likely to take a cautious approach towards notifying where there is any doubt about whether or not the regime applies. Given the broad definitions of the sectors, the low thresholds for a notifiable acquisition or trigger event and the inclusion of intellectual property licensing in the regime, a significant number of transactions in the life sciences sector could be caught and are likely to be notified at least at the outset of the regime. The costs and delays this will add to transactions should be considered at an early stage and appropriate advice sought in order to manage this as efficiently as possible.
About the authors
Adrian Toutoungi is a partner at Taylor Wessing LLP. He is a seasoned IP lawyer who relishes immersing himself in his client’s technology, product roadmap and patent/IP strategy. He is regularly involved in the negotiation and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.
Rebecca Le Flufy is an associate in Taylor Wessing LLP’s Corporate Technology group. She specialises in advising investors and technology-focused companies on venture capital investments, M&A transactions, establishing and growing their business in the UK and across Europe, and general corporate matters.
As partner at Taylor Wessing LLP, Ross McNaughton’s practice focuses on helping tech and life sciences companies in all aspects of their growth, capital raising and international expansion. He has extensive experience of a variety of venture financing and public capital raisings, mergers and acquisitions and general corporate advice, with a particular specialism in transactions with a transatlantic component.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.